Business
BioElectronics’ Chairman Discusses Recent Clinical Research Findings
BioElectronics’ Chairman Discusses Recent Clinical Research Findings.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n Company Receives Initial Purchase Order From Stada MENA FREDERICK, MD, July 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announced via a Shareholder’s update that the Company has completed and undertaken additional clinical research and has received the initial stocking purchase order from its distribution partner, Stada.  The update is below: Dear Shareholders, I would like to take this opportunity to discuss some new developments and their possible implications for the Company. Let me start by again stating our guiding principles, that is, our core capabilities are in innovation with pulsed shortwave therapy (PSWT) and manufacturing an affordable medical device. With this in mind, I would like to provide information on a few very promising new developments. Canine Osteoarthritis We recently completed a randomized, double-blind, placebo-controlled (RCT) study on providing pain relief and improving functionality for dogs suffering from osteoarthritis (OA). The owners of the dogs receiving the active device reported their dogs showed a 45% reduction in pain within 14 days compared to the dogs who received the placebo device. (Pain levels were measured via eight behavioral indicators.)  In addition, these treatment dogs exhibited increased range of motion while the placebo dogs showed no such increase. (A paper describing this study is in preparation for submission to a veterinary journal and will be posted on our website by the end of this month). These results have at least two major implications. First, canine OA is found in at least 80% of older dogs and represents a new market for BIEL with few good competitive options for dog owners. We plan to investigate how best to enter this multi-billion-dollar market in the near future.  Second, because we placed the device on the dog’s neck near the cervical spinal cord and not near the arthritic joint, it provides new evidence on how PSWT works. This latter knowledge is extremely important since it provides insights into coming up with new applications. Phantom Limb Pain A recent case study was published that used our RecoveryRx medical device to help relieve phantom limb pain. It found that 67% of the users got pain relief after usi...